Earnings Release • Aug 6, 2012
Earnings Release
Open in ViewerOpens in native device viewer
+ 9 % \$ 3,428 million Net revenue
+ 16 % \$ 589 million
Operating income (EBIT)
+ 11 %
Net income attributable to shareholders of Fresenius Medical Care AG& Co. KGaA
+ 10 %
\$ 0.95
Earnings per ordinary share
Earnings excluding investment gain:
Net income attributable to shareholders of Fresenius Medical Care AG& Co. KGaA
+ 5 %
\$ 0.91
Earnings per ordinary share
+ 9 % \$ 6,677 million Net revenue
+ 14 % \$ 1,092 million Operating income (EBIT)
+ 37 % \$ 660 million
Net income attributable to shareholders of Fresenius Medical Care AG& Co. KGaA
+ 36 % \$ 2.17
Earnings per ordinary share
Earnings excluding investment gain:
+ 8 % \$ 520 million Net income attributable to shareholders of
Fresenius Medical Care AG& Co. KGaA
+ 7 % \$ 1.71 Earnings per ordinary share
Fresenius Medical Care AG & Co. KGaA (the "company" or "Fresenius Medical Care"; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world's largest provider of dialysis products and services, today announced its results for the second quarter and first half of 2012.
Net revenue for the second quarter of 2012 increased by 9% to \$3,428 million (+ 13% at constant currency) compared to the second quarter of 2011. Organic revenue growth worldwide was 4%. Dialysis services revenue grew by 13% to \$2,605 million (+ 16% at constant currency) and dialysis product revenue decreased by 1% to \$823 million and increased by + 6% at constant currency.
North America revenue for the second quarter of 2012 increased by 14% to \$2,249 million. Dialysis services revenue grew by 15% to \$2,043 million with a same market growth of 4%. Average revenue per treatment for U.S. clinics increased to \$351 in the second quarter of 2012 compared to \$348 for the corresponding quarter in 2011. Dialysis product revenue increased by 3% to \$206 million mainly as a result of higher sales of hemodialysis products.
International revenue increased by 1% to \$1,171 million (+ 11% at constant currency). Organic revenue growth was 6%. Dialysis services revenue increased by 5% to \$562 million (+ 16% at constant currency). Dialysis product revenue decreased by 3% to \$609 million and increased by 6% at constant currency, mainly driven by higher sales of dialysis machines and dialyzers.
Operating income (EBIT ) for the second quarter of 2012 increased by 16% to \$589 million compared to \$510 million in the second quarter of 2011. This resulted in an operating margin of 17.2% for the second quarter of 2012 compared to 16.2% for the corresponding quarter in 2011.
In North America, the operating margin increased from 17.7% to 19.2%. Average costs per treatment for U.S. clinics decreased by \$3 to \$280 in the second quarter of 2012 as compared to \$283 in the second quarter of 2011.
In the International segment, the operating margin increased from 17.5% to 17.7%.
Net interest expense for the second quarter of 2012 was \$104 million, compared to \$75 million in the second quarter of 2011. This development was mainly attributable to the higher level of financial debt as a result of the issuance of various tranches of senior notes over the course of 2011 and 2012.
Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA for the second quarter of 2012 was \$289 million, an increase of 11% compared to the corresponding quarter of 2011. This includes a non-taxable investment gain of \$13 million related to the acquisition of Liberty Dialysis Holdings, Inc., including its 51% stake in Renal Advantage Partners, LLC (RAI). The gain is a result of measuring the 49% equity interest in RAI held by the company at its fair value at the time of the Liberty acquisition and represents an adjustment to the amount recorded in the first quarter of 2012 as part of the continuing finalization of the Liberty purchase accounting. Excluding this investment gain net income attributable to shareholders of Fresenius Medical Care AG& Co. KGaA increased by 6% to \$276 million.
4
Income tax expense was \$172 million for the second quarter of 2012 compared to \$149 million in the second quarter of 2011, reflecting effective tax rates of 34.6% and 34.2%, respectively. Excluding the investment gain the effective tax rate was 35.5%.
Earnings per ordinary share (EPS) for the second quarter of 2012 was \$0.95 and \$0.91 if excluding the investment gain. This represents an increase compared to the second quarter of 2011 of 10% and of 5%, respectively. The weighted average number of ordinary shares outstanding for the second quarter of 2012 was approximately 300.4 million shares, compared to 298.6 million shares for the second quarter of 2011. The increase in shares outstanding resulted from stock option exercises in the past 12 months.
In the second quarter of 2012, the company generated \$451 million in cash from operations, an increase of 45% compared to the corresponding figure last year and representing 13.2% of revenue. The cash flow generation was supported by a favorable development of days sales outstanding.
A total of \$151 million was spent for capital expenditures, net of disposals. Free cash flow before acquisitions was \$300 million compared to \$194 million in the second quarter of 2011. A total of \$6 million in cash was generated from divestitures, net of acquisitions. Free cash flow after acquisitions and divestitures was \$306 million, compared to minus \$590 million in the second quarter of 2011.
Net revenue for the first half of 2012 increased by 9% to \$6,677 million (+12% at constant currencies) compared to the first half of 2011. Organic revenue growth was 4% in the first half of 2012.
Operating income (EBIT ) for the first half of 2012 increased by 14% to \$1,092 million compared to \$955 million in the first half of 2011. The operating income margin increased to 16.4% for the first half of 2012 as compared to 15.6% in the same period in 2011.
Net interest expense for the first half of 2012 was \$203 million compared to \$146 million in the same period of 2011.
For the first half of 2012, net income attributable to shareholders of Fresenius Medical Care AG& Co. KGaA was \$660 million, up by 37% from the first half of 2011. This includes a non-taxable investment gain of \$140 million related to the acquisition of Liberty Dialysis Holdings, Inc., including its 51% stake in Renal Advantage Partners, LLC (RAI). The gain is a result of measuring the 49% equity interest in RAI held by the company at its fair value at the time of the Liberty acquisition. Excluding this investment gain net income attributable to shareholders of Fresenius Medical Care AG& Co. KGaA increased by 8% to \$520 million.
Income tax expense for the first half of 2012 was \$309 million compared to \$273 million in the same period in 2011, reflecting effective tax rates of 30.1% and 33.8%, respectively. Excluding the investment gain the effective tax rate was 34.8%.
In the first half of 2012, earnings per ordinary share rose by 36% to \$2.17 and by 7% to \$1.71 if excluding the investment gain. The weighted average number of ordinary shares outstanding during the first half of 2012 was approximately 300.3 million.
Cash from operations during the first half of 2012 was \$932 million compared to \$487 million for the same period in 2011, representing 14% of revenue.
A total of \$274 million in cash was spent for capital expenditures, net of disposals. Free cash flow before acquisitions for the first half of 2012 was \$658 million compared to \$256 million in the same period in 2011. A total of \$1,520 million in cash was spent for acquisitions, net of divestitures. Free cash flow after acquisitions and divestitures was minus \$862 million compared to minus \$866 million in the first half of last year.
Please refer to the attachments for a complete overview on the second quarter and first half of 2012 and the reconciliation of non-GAAP financial measures included in this release to the most comparable GAAP financial measures.
As of June 30, 2012, Fresenius Medical Care treated 256,456 patients worldwide, which represents a 14% increase compared to the previous year's figure. North America provided dialysis treatments for 164,058 patients, an increase of 17%. Including 28 clinics managed by Fresenius Medical Care North America, the number of patients in North America was 166,282. The International segment provided dialysis treatment to 92,398 patients, an increase of 7% over the prior year's figure.
As of June 30, 2012, the company operated a total of 3,123 clinics worldwide, which represents a 10% increase compared to the previous year's figure. The number of clinics is comprised of 2,046 clinics in North America (2,074 including managed clinics), and 1,077 clinics in the International segment, representing an increase of 12% and 6%, respectively.
During the first half of 2012, Fresenius Medical Care delivered approximately 18.89 million dialysis treatments worldwide. This represents an increase of 14%, compared to last year's figure. North America accounted for 11.89 million treatments, an increase of 12%. The International segment delivered 7.0 million treatments, an increase of 18%.
As of June 30, 2012, Fresenius Medical Care had 84,194 employees (full-time equivalents) worldwide, compared to 79,159 employees at the end of 2011. This increase of more than 5,000 employees is due to overall growth in the company's business and acquisitions including Liberty Dialysis Holdings, Inc.
The ratio of debt to earnings before interest, taxes, depreciation and amortization (EBITDA) increased from 2.77 at the end of the second quarter of 2011 to 2.92 at the end of the second quarter of 2012. The debt/ EBITDA ratio at the end of 2011 was 2.69.
Moody's affirmed the company's corporate credit as 'Ba1' with a 'stable' outlook, and Fitch rates the company's corporate credit as 'BB+' with a 'stable' outlook. Standard & Poor's placed the company's corporate credit on review as 'BB+' with a possible downgrade from 'stable' to 'negative'. For further information on Fresenius Medical Care's credit ratings, maturity profiles and credit instruments, please visit our website at www.fmc-ag.com / Investor Relations / Credit Relations.
For the full year 2012, the company confirms its sales and earnings outlook.
The company expects revenue to grow to ~ \$14 billion in 20121 .
Net income is expected to grow to ~ \$ 1.3 billion and net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to grow to ~ \$1.14 billion1 . This does not include the investment gain in the amount of \$140 million in the first half of 2012.
For 2012, the company expects to spend ~ \$700 million on capital expenditures and ~ \$1.8 billion on acquisitions. The debt/ EBITDA ratio is expected to be below 3.0 by the end of 2012.
Ben Lipps, chief executive officer of Fresenius Medical Care, commented: "We achieved a very good operating performance in the second quarter of 2012. We are very pleased with the progress we and our clinical associates are achieving to improve global patient care outcomes, notably in anemia and nutrition management and the continued reduction in hospital days. North America is progressing well with its integration of the Liberty acquisition. Revenue growth in both North America and International was double digit in constant currency and despite the difficult global economic environment, we have improved cash collection, which also reflects the dedication of our staff and credibility we have with payers. In summary, we are affirming our guidance for the full year 2012 and expect another record year for the company."
1 We define the ~ sign as a +/– 0-2% deviation from the resepective numbers.
Fresenius Medical Care will hold a conference call to discuss the results of the second quarter and first half of 2012 on Wednesday, August 1, 2012, at 3.30 p.m. CEDT / 9.30 a.m. EDT. The company invites investors to view the live webcast of the call at the company's website www.fmc-ag.com in the "Investor Relations" section. A replay will be available shortly after the call.
Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.1 million individuals worldwide. Through its network of 3,123 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 256,456 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.
For more information about Fresenius Medical Care, visit the company's website at www.fmc-ag.com.
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG&Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG&Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
| Statement of | Ea rnings | |||||
|---|---|---|---|---|---|---|
| in US\$ thousands, except share data, unaudited |
Table 1 | |||||
| Three months ended June 30, | Six months ended June 30, | |||||
| 2012 | 2011 | Change | 2012 | 2011 | Change | |
| Revenue | ||||||
| Dialysis care | 2,675,422 | 2,361,563 | 13.3% | 5,219,481 | 4,646,879 | 12.3% |
| Less: patient service bad debt provision | 70,303 | 56,429 | 24.6% | 137,162 | 108,966 | 25.9% |
| Net dialysis care | 2,605,119 | 2,305,134 | 13.0% | 5,082,319 | 4,537,913 | 12.0% |
| Dialysis products | 822,854 | 832,489 | –1.2% | 1,594,409 | 1,583,561 | 0.7% |
| Total net revenue | 3,427,973 | 3,137,623 | 9.3% | 6,676,728 | 6,121,474 | 9.1% |
| Cost of revenue | 2,301,099 | 2,108,617 | 9.1% | 4,480,345 | 4,144,581 | 8.1% |
| Gross profit | 1,126,874 | 1,029,006 | 9.5% | 2,196,383 | 1,976,893 | 11.1% |
| Selling, general and administrative | 539,616 | 501,559 | 7.6% | 1,092,448 | 985,795 | 10.8% |
| Gain on sale of dialysis clinics | (24,647) | – | (33,961) | – | ||
| Research and development | 26,938 | 26,783 | 0.6% | 55,460 | 52,932 | 4.8% |
| Income from equity method investees | (3,858) | (8,880) | –56.5% | (9,355) | (16,462) | –43.2% |
| Oper ating income (EBIT) | 588,825 | 509,544 | 15.6% | 1,091,791 | 954,628 | 14.4% |
| Investment gain | (12,915) | – | (139,600) | – | ||
| Interest income | (12,496) | (15,579) | –19.8% | (32,802) | (26,000) | 26.2% |
| Interest expense | 116,691 | 90,183 | 29.4% | 235,877 | 172,169 | 37.0% |
| Interest expense, net | 104,195 | 74,604 | 39.7% | 203,075 | 146,169 | 38.9% |
| Income before taxes | 497,545 | 434,940 | 14.4% | 1,028,316 | 808,459 | 27.2% |
| Income tax expense | 172,241 | 148,856 | 15.7% | 309,318 | 273,260 | 13.2% |
| Net income | 325,304 | 286,084 | 13.7% | 718,998 | 535,199 | 34.3% |
| Less: Net income attributable | ||||||
| to noncontrolling interests | 35,967 | 25,323 | 42.0% | 59,163 | 53,737 | 10.1% |
| Net income ATTRI BUTA BLE |
||||||
| TO sh a reholders of FMC AG & CO . KGa A |
289,337 | 260,761 | 11.0% | 659,835 | 481,462 | 37.0% |
| Oper ating income (EBIT) | 588,825 | 509,544 | 15.6% | 1,091,791 | 954,628 | 14.4% |
| Depreciation and amortization | 150,877 | 136,289 | 10.7% | 294,251 | 272,273 | 8.1% |
| EBITDA | 739,702 | 645,833 | 14.5% | 1,386,042 | 1,226,901 | 13.0% |
| Earnings per ordinary share | \$0.95 | \$0.86 | 10.3% | \$2.17 | \$1.59 | 36.2% |
| Ea rnings per ordina ry AD S |
\$0.95 | \$0.86 | 10.3% | \$2.17 | \$1.59 | 36.2% |
| Weighted average number of shares | ||||||
| Ordinary shares | 300,415,725 | 298,559,749 | 300,310,425 | 298,427,098 | ||
| Preference shares | 3,966,600 | 3,958,515 | 3,966,301 | 3,957,978 | ||
| In percent of revenue | ||||||
| Cost of revenue Gross profit |
67.1% 32.9% |
67.2% 32.8% |
67.1% 32.9% |
67.7% 32.3% |
||
| Selling, general and administrative | 15.7% | 16.0% | 16.4% | 16.1% | ||
| Gain on sale of dialysis clinics | –0.7% | – | –0.5% | – | ||
| Research and development | 0.8% | 0.9% | 0.8% | 0.9% | ||
| Income from equity method investees | –0.1% | –0.3% | –0.1% | –0.3% | ||
| Oper ating income (EBIT) | 17.2% | 16.2% | 16.4% | 15.6% | ||
| Investment gain | –0.4% | – | –2.1% | – | ||
| Interest expense, net | 3.0% | 2.4% | 3.0% | 2.4% | ||
| income BEFORE taxes |
14.5% | 13.9% | 15.4% | 13.2% | ||
| Income tax expense | 5.0% | 4.7% | 4.6% | 4.5% | ||
| Net income attributable to noncontrolling | ||||||
| interests | 1.0% | 0.8% | 0.9% | 0.9% | ||
| Net income ATTRI BUTA BLE |
||||||
| TO sh a reholders of FMC AG & CO . KGa A |
8.4% | 8.3% | 9.9% | 7.9% | ||
| EBITDA | 21.6% | 20.6% | 20.8% | 20.0% |
| Segment a nd other Inform ation | ||||||
|---|---|---|---|---|---|---|
| in US\$ million, except employees, unaudited |
Table 2 | |||||
| Three months ended June 30, | Six months ended June 30, | |||||
| 2012 | 2011 | Change | 2012 | 2011 | Change | |
| Net revenue | ||||||
| North America | 2,249 | 1,971 | 14.1% | 4,353 | 3,896 | 11.7% |
| International | 1,171 | 1,163 | 0.7% | 2,307 | 2,217 | 4.0% |
| Corporate | 8 | 4 | 100.3% | 17 | 8 | 104.4% |
| Total net revenue | 3,428 | 3,138 | 9.3% | 6,677 | 6,121 | 9.1% |
| Operating income (EBIT) | ||||||
| North America | 431 | 348 | 23.7% | 779 | 661 | 17.9% |
| International | 207 | 203 | 2.0% | 402 | 374 | 7.5% |
| Corporate | (49) | (41) | 17.7% | (89) | (80) | 11.5% |
| total Operating income (EBIT) | 589 | 510 | 15.6% | 1,092 | 955 | 14.4% |
| Operating income in percent of revenue | ||||||
| North America | 19.2% | 17.7% | 17.9% | 17.0% | ||
| International | 17.7% | 17.5% | 17.4% | 16.9% | ||
| total | 17.2% | 16.2% | 16.4% | 15.6% | ||
| Employees | ||||||
| Full-time equivalents | 84,194 | 77,081 |
| in US\$ million, | |
|---|---|
| unaudited |
| Three months ended June 30, | Six months ended June 30, | |||
|---|---|---|---|---|
| 2012 | 2011 | 2012 | 2011 | |
| Segment information North America | ||||
| net revenue | 2,249 | 1,971 | ||
| Costs of revenue and research and development | 1,534 | 1,358 | ||
| Selling, general and administrative | 317 | 274 | ||
| Gain on sale of dialysis clinics | (25) | – | ||
| Income from equity method investees | (8) | (9) | ||
| Costs of revenue a nd oper ating expenses | 1,818 | 1,623 | ||
| Oper ating income (EBIT) | 431 | 348 | ||
| In percent of revenue | 19.2% | 17.7% | ||
| Dialysis products revenue incl. and excl. internal sales | ||||
| North America | ||||
| Dialysis products revenue incl. internal sales | 400 | 394 | ||
| Less internal sales | (194) | (195) | ||
| Dialysis products external sales | 206 | 199 | ||
| International | ||||
| Dialysis products revenue incl. internal sales | 712 | 728 | ||
| Less internal sales | (103) | (99) | ||
| Dialysis products external sales | 609 | 629 | ||
| Reconciliation of cash flow from operating activities to EBITDA 1 |
||||
| Total EBITDA | 1,386 | 1,227 | ||
| Interest expense, net | (203) | (146) | ||
| Income tax expense | (309) | (273) | ||
| Change in working capital and other non-cash items | 58 | (321) | ||
| Net cash provided by oper ating activities | 932 | 487 | ||
| Annualized EBITDA 2 |
||||
| Oper ating income (EBIT) last twelve months |
2,349 | 1,987 | ||
| Depreciation and amortization last twelve months | 603 | 530 | ||
| Non-cash charges | 53 | 50 | ||
| Annualized EBITDA | 3,005 | 2,567 |
1 EBITDA is the basis for determining compliance with certain covenants in Fresenius Medical Care's long-term debt instruments.
2 EBITDA 2012: Pro forma numbers including Liberty Dialysis Holdings Inc., after FTC mandated divestitures.
| Bala nce Sheet Table 4 in US\$ million |
||
|---|---|---|
| June 30, 2012 |
December 31, 2011 |
|
| unaudited | audited | |
| Assets | ||
| Current assets | 6,063 | 5,695 |
| Intangible assets | 11,894 | 9,873 |
| Other non-current assets | 3,787 | 3,965 |
| Total ass ets |
21,744 | 19,533 |
| Liabilities and equity | ||
| Current liabilities | 5,870 | 4,263 |
| Long-term liabilities | 6,861 | 6,799 |
| Noncontrolling interests subject to put provisions | 541 | 410 |
| Total equity | 8,472 | 8,061 |
| Total liabilities AND equity |
21,744 | 19,533 |
| Eq uity / ass ets r atio |
39% | 41% |
| Debt | ||
| Short-term borrowings | 103 | 99 |
| Short-term borrowings from related parties | 52 | 28 |
| Current portion of long-term debt and capital lease obligations | 3,086 | 1,589 |
| Long-term debt and capital lease obligations, less current portion | 5,543 | 5,495 |
| Total debt | 8,784 | 7,211 |
Fresenius Medical Care 2012
| Investor News | ||||
|---|---|---|---|---|
| August 1, 2012 |
| Cash flow Statement | ||
|---|---|---|
| Table 5 Six months ended June 30, |
||
| in US\$ million, unaudited | ||
| 2012 | 2011 | |
| Operating activities | ||
| Net income | 720 | 536 |
| Depreciation/amortization | 294 | 272 |
| Investment gain | (140) | – |
| Change in working capital and other non-cash items | 58 | (321) |
| Cash Flow from oper ating activities | 932 | 487 |
| Investing activities | ||
| Purchases of property, plant and equipment | (277) | (238) |
| Proceeds from sale of property, plant and equipment | 3 | 7 |
| Capital expenditures, net | (274) | (231) |
| Free Cash Flow | 658 | 256 |
| Acquisitions, net of cash acquired, and purchases of intangible assets | (1,748) | (1,122) |
| Proceeds from divestitures | 228 | 0 |
| Acquisitions, net of divestitures | (1,520) | (1,122) |
| Free Cash Flow after investing Activities | (862) | (866) |
| Financing activities | ||
| Change in accounts receivable securitization program | (83) | 130 |
| Change in intercompany debt | 25 | 146 |
| Change in other debt | 1,463 | 1,419 |
| Proceeds from exercise of stock options | 23 | 32 |
| Distributions to noncontrolling interests | (79) | (62) |
| Contributions from noncontrolling interests | 12 | 12 |
| Dividends paid | (272) | (281) |
| Cash Flow from fina ncing activities | 1,089 | 742 |
| Effects of exchange rates on cash | (7) | 50 |
| SE (Decrease) in cash Net INCREA |
220 | (74) |
| Cash at beginning of period | 457 | 523 |
| Cash at end of period | 677 | 449 |
Fresenius Medical Care 2012
| ua rterly Perform a nce Scoreca rd – | ||||
|---|---|---|---|---|
| Three months ended June 30, | Revenue | |||
| in US\$ thousands, except per-treatment revenue, unaudited |
Table 6 | |||
| 2012 | cc | 2011 | cc | |
| North America | ||||
| Net revenue | 2,248,692 | 1,970,990 | ||
| Growth year-over-year | 14.1% | 0.0% | ||
| net Dialysis Ca re |
2,043,127 | 1,771,515 | ||
| Growth year-over-year | 15.3% | 0.6% | ||
| U.S. per treatment | 351 | 348 | ||
| Per treatment | 344 | 340 | ||
| Sequential growth | –0.5% | –0.1% | ||
| Growth year-over-year | 1.1% | –2.4% | ||
| Dialysis products | ||||
| Incl. internal sales | 399,979 | 394,413 | ||
| Growth year-over-year | 1.4% | 1.2% | ||
| External sales | 205,565 | 199,475 | ||
| Growth year-over-year | 3.1% | –4.7% | ||
| International | ||||
| Net revenue | 1,170,902 | 1,162,448 | ||
| Growth year-over-year | 0.7% | 10.8% | 26.4% | 14.8% |
| net Dialysis Ca re |
561,992 | 533,618 | ||
| Growth year-over-year | 5.3% | 16.3% | 31.1% | 19.6% |
| Per treatment | 159 | 176 | 178 | 162 |
| Sequential growth | –1.4% | 3.5% | ||
| Growth year-over-year | –10.4% | –1.0% | 11.7% | 1.9% |
| Dialysis products | ||||
| Incl. internal sales | 711,970 | 728,130 | ||
| Growth year-over-year | –2.2% | 7.6% | 22.6% | 10.9% |
| External sales | 608,910 | 628,830 | ||
| Growth year-over-year | –3.2% | 6.1% | 22.7% | 10.9% |
cc = constant currency
Changes in revenue include the impact of changes in foreign currency exchange rates. We use the non-GAAP financial measure "at constant exchange rates" in our filings to show changes in our revenue without giving effect to period-to-period currency fluctuations. Under U.S. GAAP, revenues received in local (non-U.S. dollar) currency are translated into U.S. dollars at the average exchange rate for the period presented. When we use the term "constant currency", it means that we have translated local currency revenues for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenues into U.S. dollars that we used to translate local currency revenues for the comparable reporting period of the prior year. We then calculate the change, as a percentage, of the current period revenues using the prior period exchange rates versus the prior period revenues. This resulting percentage is a non-GAAP measure referring to a change as a percentage "at constant exchange rates".
We believe that revenue growth is a key indication of how a company is progressing from period to period and that the non-GAAP financial measure constant currency is useful to investors, lenders, and other creditors because such information enables them to gauge the impact of currency fluctuations on its revenue from period to period. However, we also believe that data on constant currency period-over-period changes have limitations, particularly as the currency effects that are eliminated could constitute a significant element of our revenue and could significantly impact our performance. We therefore limit our use of constant currency period-over-period changes to a measure for the impact of currency fluctuations on the translation of local currency revenue into U.S. dollars. We do not evaluate our results and performance without considering both constant currency period-over-period changes in non-U.S. GAAP revenue on the one hand and changes in revenue prepared in accordance with U.S. GAAP on the other. We caution the readers of this report to follow a similar approach by considering data on constant currency period-over-period changes only in addition to, and not as a substitute for or superior to, changes in revenue prepared in accordance with U.S. GAAP. We present the fluctuation derived from U.S. GAAP revenue next to the fluctuation derived from non-GAAP revenue. Because the reconciliation is inherent in the disclosure, we believe that a separate reconciliation would not provide any additional benefit.
13
Three months ended June 30, unaudited
| 2012 | 2011 | |
|---|---|---|
| North America | ||
| Number of treatments | 6,141,414 | 5,379,508 |
| Treatments per day | 78,736 | 68,968 |
| Per day sequential growth | 6.9% | 1.3% |
| Per day year-over-year growth | 14.2% | 3.7% |
| Same market growth year-over-year | 3.6% | 3.2% |
| International | ||
| Number of treatments | 3,531,153 | 3,004,965 |
| Same market growth year-over-year | 3.9% | 5.2% |
| Qua rterly Perform a nce Scoreca rd – | ||
|---|---|---|
| Expenses | ||
| Three months ended Table 8 June 30, unaudited |
||
| 2012 | 2011 | |
| North America | ||
| Costs of revenue and operating expenses, gain on sale of dialysis clinics and income from equity method investees |
||
| In percent of revenue | 80.8% | 82.3% |
| Selling, general and administrative | ||
| In percent of revenue | 14.1% | 13.9% |
| U.S. Dialysis care operating expenses/treatment in US\$ | 280 | 283 |
| Sequential growth | –2.1% | –1.9% |
| Growth year-over-year | –0.9% | –3.3% |
| Dialysis care operating expenses/treatment in US\$ | 275 | 277 |
| Sequential growth | –2.0% | –2.0% |
| Growth year-over-year | –0.7% | –3.5% |
| Total Group | ||
| Costs of revenue and operating expenses, gain on sale of dialysis clinics and income from equity method investees |
||
| In percent of revenue | 82.8% | 83.8% |
| Selling, general and administrative | ||
| In percent of revenue | 15.7% | 16.0% |
| Effective tax rate | 34.6% | 34.2% |
14
| Qua rterly Perform a nce Scoreca rd – | |||
|---|---|---|---|
| Three months ended June 30, in US\$ thousands, except number of de novos, unaudited |
Cash Flow / Investing Activities Table 9 |
||
| 2012 | 2011 | ||
| Total Group | |||
| Operating cash flow | 450,783 | 311,244 | |
| In percent of revenue | 13.2% | 9.9% | |
| Free cash flow before acquisitions | 299,593 | 194,108 | |
| In percent of revenue | 8.7% | 6.2% | |
| Acquisitions and investments, net of divestitures | –6,108 | 783,666 | |
| Capital expenditures, net | 151,190 | 117,136 | |
| In percent of revenue | 4.4% | 3.7% | |
| Maintenance | 87,802 | 66,615 | |
| In percent of revenue | 2.6% | 2.1% | |
| Growth | 63,388 | 50,521 | |
| In percent of revenue | 1.8% | 1.6% | |
| Number of de novos | 21 | 7 | |
| North America | 16 | 4 | |
| International | 5 | 3 |
| June 30, unaudited | Qua rterly Perform a nce Scoreca rd – Bala nce Sheet Table 10 |
||
|---|---|---|---|
| 2012 | 2011 | ||
| Total Group | |||
| Debt in US\$ million | 8,784 | 7,114 | |
| Debt/EBITDA | 2.9 | 2.8 | |
| North America | |||
| Days sales outstanding | 54 | 59 | |
| International | |||
| Days sales outstanding | 120 | 121 |
| Qua rterly Perform a nce Scoreca rd | ||
|---|---|---|
| Table 11 Three months ended June 30, |
||
| 2012 | 2011 | |
| North America (U.S.) Clinical Performance |
||
| Single Pool Kt/ v > 1.2 | 97% | 97% |
| Hemoglobin = 10 – 12 g /dl | 77% | 75% |
| Hemoglobin = 10 – 13 g /dl | 83% | 89% |
| Calcium = 8.4 – 10.2 mg /dl | 83% | 79% |
| Albumin > = 3.5 g /dl1 | 86% | 84% |
| No catheter | 79% | 77% |
| Phosphate < = 5.5mg /dl | 65% | 63% |
| Hospitalization days per patient (12 months ending June 30) | 9.7 | 9.8 |
| Demographics | ||
| Average age in years | 62 | 62 |
| Average time on dialysis in years | 3.8 | 3.7 |
| Average body weight in kg | 81 | 81 |
| Prevalence of diabetes | 58% | 56% |
| Europe, Middle East and Africa Clinical Performance |
||
| Single Pool Kt/ v > 1.2 | 96% | 96% |
| Hemoglobin = 10 – 12 g /dl | 59% | 57% |
| Hemoglobin = 10 – 13 g /dl | 78% | 78% |
| Calcium = 8.4 – 10.2 mg /dl | 76% | 77% |
| Albumin > = 3.5 g /dl1 | 88% | 89% |
| No catheter | 81% | 81% |
| Phosphate < = 5.5mg /dl | 77% | 74% |
| Hospitalization days per patient (12 months ending June 30) | 9.2 | 9.6 |
| Demographics | ||
| Average age in years | 64 | 64 |
| Average time on dialysis in years | 5.2 | 5.0 |
| Average body weight in kg | 71 | 71 |
| Prevalence of diabetes | 27% | 28% |
1 International standard BCR CRM470
Investor Relations 61346 Bad Homburg v.d.H. Germany www.fmc-ag.com
Head of Investor Relations & Corporate Communications Tel. + 4961726092601 Fax + 4961726092301 E-Mail: [email protected]
Investor Relations
Terry L. Morris Tel. + 1 800 948 25 38 Fax + 1 615 345 56 05 E-Mail: [email protected]
Published by Fresenius Medical Care AG & Co. KGaA Investor Relations
Annual reports, interim reports and further information on the Company is also available on our website. Please visit us at www.fmc-ag.com
For printed material, please contact Investor Relations.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.